Patents by Inventor Gordon Power

Gordon Power has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-Vista Antibodies And Fragments, Uses Thereof, And Methods Of Identifying Same
    Publication number: 20170320950
    Abstract: The present invention relates to antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of eliciting certain biological responses using the antibodies. Compositions and methods of using anti-VISTA antibodies in combination with one or more antibodies that bind to immune checkpoint proteins are also provided.
    Type: Application
    Filed: April 6, 2017
    Publication date: November 9, 2017
    Inventors: Linda A. Snyder, Gordon Powers, Enrique Zudaire Ubani, Douglas Matthew Marvel
  • ANTI-VISTA ANTIBODIES AND FRAGMENTS, USES THEREOF, AND METHODS OF IDENTIFYING SAME
    Publication number: 20170233479
    Abstract: The present invention relates to antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of eliciting certain biological responses using the antibodies. Methods of identifying anti-VISTA antibodies capable of eliciting certain biological responses are also included.
    Type: Application
    Filed: February 10, 2017
    Publication date: August 17, 2017
    Inventors: Linda A. Snyder, Gordon Powers, Enrique Zudaire Ubani, Douglas Matthew Marvel
  • ANTIBODIES SPECIFICALLY BINDING PD-1, TIM-3 OR PD-1 AND TIM-3 AND THEIR USES
    Publication number: 20170121409
    Abstract: The present invention relates to antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Application
    Filed: November 1, 2016
    Publication date: May 4, 2017
    Applicant: Janssen Biotech, Inc.
    Inventors: Raluca Verona, Gordon Powers, Nina Chi Sabins, Nikki A. DeAngelis, Sandra Santulli-Marotto, Karla R. Wiehagen
  • Anti-VISTA Antibodies And Fragments
    Publication number: 20170051061
    Abstract: The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.
    Type: Application
    Filed: December 22, 2014
    Publication date: February 23, 2017
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Linda Snyder, Gordon Powers
  • Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof
    Patent number: 8691864
    Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: April 8, 2014
    Inventors: Nigel H. Greig, Karen T. Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Tada Utsuki, Timothy T. Soncrant, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane M. Davidson, Michael Sturgess
  • Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof
    Publication number: 20120295946
    Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.
    Type: Application
    Filed: July 26, 2012
    Publication date: November 22, 2012
    Inventors: Nigel H. Greig, Karen T.Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Tada Utsuki, Timothy T. Soncrant, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane M. Davidson, Michael Sturgess
  • Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof
    Patent number: 8258172
    Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.
    Type: Grant
    Filed: July 22, 2010
    Date of Patent: September 4, 2012
    Assignees: Raptor Pharmaceutical Corp, National Institutes of Health (NIH)
    Inventors: Nigel H. Greig, Karen T. Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Tada Utsuki, Timothy T. Soncrant, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane M. Davidson, Michael Sturgess
  • Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof
    Publication number: 20110021594
    Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.
    Type: Application
    Filed: July 22, 2010
    Publication date: January 27, 2011
    Inventors: Nigel H. Greig, Karen T.Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Tada Utsuki, Timothy T. Soncrant, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane Davidson, Michael Sturgess
  • Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof
    Patent number: 7786162
    Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: August 31, 2010
    Assignees: Raptor Pharmaceutical Corp., National Institutes of Health (NIH)
    Inventors: Nigel H. Greig, Karen T. Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Tada Utsuki, Timothy T. Soncrant, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane M. Davidson, Michael Sturgess
  • Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof
    Publication number: 20090131501
    Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.
    Type: Application
    Filed: January 21, 2009
    Publication date: May 21, 2009
    Applicants: TorreyPines Therapeutics, National Institutes of Health (NIH)
    Inventors: Nigel H. Greig, Karen T.Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Tada Utsuki, Timothy T. Soncrant, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane Davidson, Michael Sturgess
  • Use of nitrite salts for the treatment of cardiovascular conditions
    Publication number: 20070154569
    Abstract: It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.
    Type: Application
    Filed: July 9, 2004
    Publication date: July 5, 2007
    Applicants: The Govt. of the U.S.A. through The Dept. of Health and Human Services, The University of Alabama Research Foundation, Wake Forest University, Loma Linda University, The Board of Supervisors of Louisiana State University
    Inventors: Mark Gladwin, Alan Schechter, David Lefer, Rakesh Patel, Christian Hunter, Gordon Power, Daniel Kim-Shapiro, Ryszard Pluta, Edward Oldfield, Richard Cannon
  • Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof
    Patent number: 7153882
    Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not tocix in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: December 26, 2006
    Assignees: The United States of America as represented by the Department of Health and Human Services, The National Institutes of Health and Axonyx, Inc.
    Inventors: Nigel H. Greig, Karen T. Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Timothy T. Sencrant, Tada Utsuki, Donald Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane Davidson, Michael Sturgess
  • Agents useful for reducing amylioid precursor protein and treating dementia and methods of use thereof
    Publication number: 20060270729
    Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.
    Type: Application
    Filed: June 20, 2006
    Publication date: November 30, 2006
    Inventors: Nigel Greig, Karen Shaw, Qiang-Sheng Yu, Harold Holloway, Tada Utsuki, Timothy Soncrant, Donald Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane Davidson, Michael Sturgess
  • Inhibitors of RNase P proteins as antibacterial compounds
    Publication number: 20050187409
    Abstract: The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones and benzoic acid compounds.
    Type: Application
    Filed: October 21, 2004
    Publication date: August 25, 2005
    Inventors: Gordon Powers, Michael Sturgess
  • User interface for composing multi-media presentations
    Publication number: 20050055377
    Abstract: A method, distributed computer system, and computer software program, stored on a computer readable medium, is configured to generate multimedia presentations. The program includes a database management system. The database management system includes audiovisual content stored in association with icons indicative of the audiovisual content and a memory buffer for storing a multimedia presentation. The memory buffer is configured to store media content in association with an exhibition time within the multimedia presentation. A server stub is configured for storing and recalling data in the database management system in accord with requests for actions received at the server stub from the client computer. The stub also generates messages to the client computer indicative of the media content stored in the memory buffer. A compiler, the compiler is configured to generate a file including the multimedia presentation stored in the memory buffer.
    Type: Application
    Filed: May 26, 2004
    Publication date: March 10, 2005
    Inventors: Richard Dorey, Gordon Powers
  • Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof
    Publication number: 20040138282
    Abstract: The present invention provides compounds and methods of administering compounds to a subject taht can reduce &bgr;APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce &bgr;APP production and that is not tocix in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease &bgr;APP production.
    Type: Application
    Filed: February 6, 2004
    Publication date: July 15, 2004
    Inventors: Nigel H. Greig, Karen T. Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Timothy T. Sencrant, Tada Utsuki, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane Davidson, Michael Sturgess